RAS inhibitors: Potential for cancer therapeutics

Molecular Medicine Today

Volumn 6, Issue 10, 2000, Pages 398-402

  Kloog, Yoel ^a   Cox, Adrienne D ^b  

^a TEL AVIV UNIVERSITY   (Israel)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; CELL SURFACE RECEPTOR; FARNESYLCYSTEINE DERIVATIVE; FARNESYLTHIOSALICYLIC ACID; GERANYLTRANSFERASE; GUANINE NUCLEOTIDE EXCHANGE FACTOR; GUANOSINE TRIPHOSPHATASE; GUANOSINE TRIPHOSPHATE; MITOGEN ACTIVATED PROTEIN KINASE; PACLITAXEL; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEINASE INHIBITOR; RAS PROTEIN; RHO FACTOR; SULINDAC; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; CLINICAL TRIAL; COLORECTAL CARCINOMA; ENZYME INHIBITION; GENE MUTATION; HUMAN; MELANOMA; NONHUMAN; ONCOGENE H RAS; ONCOGENE K RAS; ONCOGENE N RAS; PANCREAS CANCER; PROTEIN PROCESSING; REVIEW;

EID: 0033803477     PISSN: 13574310     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1357-4310(00)01789-5     Document Type: Review

References (30)

1. The Ras branch of small GTPases: Ras family members don't fall far from the tree
2. The Ras-GAP complex: Structural basis for GTPase activation and its loss in oncogenic Ras mutants
3. Ras oncogenes in human cancer: A review
4. Altered growth of human colon cancer cell lines disrupted at activated Ki-ras
5. Loss of oncogenic ras expression does not correlate with loss of tumorigenicity in human cells
6. Farnesyltransferase inhibitors and cancer treatment: Targeting simply Ras?
7. All ras proteins are polyisoprenylated but only some are palmitoylated
8. Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor
9. p21ras is modified by a farnesyl isoprenoid
10. Benzodiazepine peptidomimetics: Potent inhibitors of ras farnesylation in animal cells
11. Selective inhibition of Ras-dependent cell growth by farnesylthiosalisylic acid
12. Dislodgment and accelerated degradation of Ras
13. Sulindac sulfide inhibits Ras signaling
14. Guanosine triphosphatase stimulation of oncogenic Ras mutants
15. Liposome-mediated in vivo gene transfer of antisense K-ras construct inhibits pancreatic tumor dissemination in the murine peritoneal cavity
16. Reovirus therapy of tumors with activated Ras pathway
17. Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice
18. Antitumor activity of SCH 66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and wap-ras transgenic mice
19. A peptidomimetic inhibitor of farnesyl: Protein transferase blocks the anchorage-dependent and-independent growth of human tumor cell lines
20. K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors
21. GGTI-298 induces G0-G1 block and apoptosis whereas FTI-277 causes G2-M enrichment in A549 cells
22. Farnesyl transferase inhibitors induce apoptosis of Ras-transformed cells denied substratum attachment
23. Farnesyltransferase inhibitors induce cytochrome c release and caspase 3 activation preferentially in transformed cells
24. Cell growth inhibition by farnesyltransferase inhibitors is mediated by gain of geranylgeranylated RhoB
25. FTIs block the farnesylation of CENP-E and CENP-F, and alter the association of CENP-E with the microtubules
26. Farnesyltransferase inhibitors: Potential role in the prevention and treatment of cancer
27. Concepts in Ras-directed therapy
28. Novel Ras antagonist blocks human melanoma growth
29. Membrane interactions of a constitutively active GFP-K-Ras 4B and their role in signaling: Evidence from lateral mobility studies
30. Peptides containing a consensus Ras binding sequence from Raf-1 and the GTPase activating protein NF1 inhibit Ras function